UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Holdings History for RECURSION PHARMACEUTICALS, INC. - Class A Common Stock (RXRX)

Symbol: RXRX on Nasdaq
Investment type: Equity / Class A Common Stock

Shares, Excluding Options vs Price

Value, Excluding Options

Holdings date	Weight	Change	Value $	Shares	Change	Activity %	Price	All Holders
31 Dec 2025	0%	-0%	$16,667,644	4,075,219	-121,759	-2.9%	$4.09	Q4 2025
30 Sep 2025	0%	-0%	$20,481,253	4,196,978	-418,538	-9.1%	$4.88	Q3 2025
30 Jun 2025	0%	-0%	$23,354,511	4,615,516	-1,793,008	-28%	$5.06	Q2 2025
31 Mar 2025	0.01%	+0.01%	$33,901,092	6,408,524	+4,149,346	+100%	$5.29	Q1 2025
31 Dec 2024	0%	+0%	$15,272,044	2,259,178	+118,428	+5.5%	$6.76	Q4 2024
30 Sep 2024	0%	+0%	$14,107,543	2,140,750	+43,078	+2.1%	$6.59	Q3 2024
30 Jun 2024	0%	+0.01%	$15,732,542	2,097,672	+1,891,903	+919%	$7.50	Q2 2024
31 Mar 2024	0%	-0%	$2,051,517	205,769	-21,104	-9.3%	$9.97	Q1 2024
31 Dec 2023	0%	+0%	$2,236,967	226,873	+15,297	+7.2%	$9.86	Q4 2023
30 Sep 2023	0%	+0%	$1,618,557	211,576	+96,298	+84%	$7.65	Q3 2023
30 Jun 2023	0%	0%	$768,904	115,278	0		$6.67	Q2 2023
31 Mar 2023	0%	+0%	$768,904	115,278	+8,347	+7.8%	$6.67	Q1 2023
31 Dec 2022	0%	+0%	$824,438	106,931	+30,052	+39%	$7.71	Q4 2022
30 Sep 2022	0%	+0%	$817,993	76,879	+25,426	+49%	$10.64	Q3 2022
30 Jun 2022	0%	+0%	$418,827	51,453	+3,259	+6.8%	$8.14	Q2 2022
31 Mar 2022	0%	+0%	$345,069	48,194	+12,741	+36%	$7.16	Q1 2022
31 Dec 2021	0%	+0%	$607,310	35,453	+35,453	NEW	$17.13	Q4 2021

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.